ALKERMES (ALKS)
Health Care · Neuroscience Pharmaceuticals · NASDAQ
Alkermes is a neuroscience-focused biopharmaceutical company developing and commercializing therapeutic treatments for complex neurological and psychiatric disorders.
What ALKERMES does
Alkermes is a global biopharmaceutical company focused on the development of medicines in the field of neuroscience. The company maintains a portfolio of proprietary products for the treatment of alcohol and opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. It also operates a pipeline of clinical and preclinical candidates targeting neurological disorders including idiopathic hypersomnia, ADHD, and fatigue associated with multiple sclerosis and Parkinson’s disease.
Themes: Neuroscience, Psychiatric disorders, Schizophrenia treatments, Bipolar disorder therapies, Narcolepsy research, Opioid dependence treatment
Fundamentals
- Price$40.11 as of 2026-10-08 close
- Market cap$6.7B as of 2026-07-23 (share count; price 2026-10-08)
- 1-year return+27.3% 2025-10-08 close $31.51 → 2026-10-08 close $40.11
- P/E104.21 as of 2026-10-08
- Net margin+16.4% FY2025, SEC XBRL
- ROE+13.3% FY2025, SEC XBRL
- Debt / equity0.83 as of 2026-09-03
- Revenue growth (YoY)+10.8% as of 2026-09-03
- Revenue CAGR (3y)+9.9% SEC XBRL
- Beta0.70 as of 2026-09-03
- Last reported earnings2026-07-28 SEC EDGAR Form 8-K (Item 2.02)
How ALKS compares in its sector
- price-to-earnings ratiotop 25% 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ALKS is not currently in any published Top 10 list. Its scores are below.
Top 10 score
51.7 #635 of 1,379 scored · #77 of 151 in Health Care
Financial health 65th (free cash flow margin 32.5%, debt to equity 0.8) and profitability 62nd (operating margin 17.2%, return on equity 13.3%); weakest is valuation (28th, price to earnings 104.2, price to book 3.7).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How ALKERMES looks technically
ALKERMES (ALKS) is trading 2.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 189 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive). It just made a new 20-day low, its first since 2026-05-28, breaking below its recent trading range. It is 28.0% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 2.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +2.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $46.18 | $46.18 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $39.24 | $39.24 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 47.66. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 189 trading days ago — a "golden cross", a bullish long-term signal | 189 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control | 31.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30) | 33.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($39.10 to $44.79) — its "stochastic" reading is 18 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 17.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 4 trading days ago (its momentum flipped positive) | 4 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $55.67 | $55.67 |
|---|---|---|
| From the 52-week high | it is 28.0% below its 52-week high (its highest price of the past year) | -27.9% |
| Above the 52-week low | it is 48.6% above its 52-week low (its lowest price of the past year) | +48.6% |
| Below the 52-week high | it is 28.0% below its highest point of the past year | 27.9% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-05-28, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-05-28, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $98.50 (set on 2000-03-01) | $98.50 |
| Given back of the 52-week move | over the past year its closes ranged ($27.20 to $55.22), and it has given back around half of its rise from last year’s low — 54% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $37.01 to $37.90. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 53.9% |
| From the all-time high | it is 59.3% below its all-time high | -59.3% |
| Nearest price level | it is trading 1.0% above a support level at $39.70 — a price it turned at twice since 2026-05-13, most recently on 2026-09-29. Since 2024-10-08 it has 11 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.0% |
| All-time low | its lowest closing price on record is $0.9375 (set on 1994-12-19) | $0.9375 |
| Above the all-time low | it is 4178.4% above its all-time low | +4,178% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 59th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.50 between its high and its low — about 3.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.50 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $38.29 and $47.20 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $38.29 – $42.75 – $47.20 |
| Typical daily range (% of price) | its price moves about 3.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.7% |
| Stretch from the 200-day average | it is trading 0.6 daily ranges above its 200-day average price (2.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.53× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.8% |
|---|---|---|
| Open gap | it gapped 6.5% below the previous close 51 sessions ago and has not traded back through the level it left behind at 52.73 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -6.5% |
| Gap filled | a 2.0% gap up opened on 2026-09-21 has been "filled" 13 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 13 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -6.2% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 12.9 percentage points (the stock lost 11.8% while the market gained 1.0%) | -12.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 29.9 percentage points (the stock lost 26.1% while the market gained 3.8%) | -29.9% |
| vs market, 6 months | over the past 6 months this stock beat the market by 0.2 percentage points (the stock gained 17.7% while the market gained 17.5%) | +0.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 12.3 percentage points (the stock gained 27.3% while the market gained 15.0%) | +12.3% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, a strong downtrend, with sellers in control, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 18% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 2.5% of the share price. | -17.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $39.30 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | +2.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 12% below the average price paid since it last reported on 2026-07-28 (its 10-Q), so the typical buyer over that stretch is under water. That average is $45.49 — a volume-weighted average of daily closes over 52 sessions, not a true tick-by-tick VWAP. | -11.8% |
Price levels it has turned at before
ALKS last closed at $40.11 on 2026-10-08. Since 2024-10-08 it has turned at 11 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $39.70 | Support | 1.0% below the last close | turned there twice · 2026-05-13 to 2026-09-29 |
| $36.38 | Support | 9.3% below the last close | turned there four times · 2025-02-18 to 2026-05-21 |
| $35.35 | Support | 11.9% below the last close | turned there six times · 2025-03-05 to 2026-04-20 |
| $47.53 | Resistance | 18.5% above the last close | turned there twice · 2026-07-29 to 2026-09-17 |
| $50.86 | Resistance | 26.8% above the last close | turned there three times · 2026-07-15 to 2026-08-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $47.66.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $42.54 and $45.55 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $39.84.
This reading has stood for 3 trading days, since 2026-10-06.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · MACD just crossed bullish (12/26/9) · At the bottom of its 14-day range (stochastic below 20) · Under water since its last earnings report (below the anchored VWAP) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.74 mean, 1=Strong Buy…5=Strong Sell) — 18 analysts
- Mean price target$56.56 range $38.00 – $83.00; median $58.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ALKS
- Consensus EPS estimate$0.2469 next reporting period, as of 2026-10-09
- Estimate change, 30 days$0.00 (0.0%) from $0.2469, on 2026-09-07, 32-day window
- Readings revised upward0% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Failure to successfully develop and commercialize clinical-stage product candidates.","Significant reliance on intellectual property and proprietary technology rights.","Intense competition in the pharmaceutical industry that could impact market share and pricing."]
What changed in the latest 10-Q
AI-assisted comparison of ALKS's 10-Q filed 2026-07-28 against the prior one filed 2026-05-05.
Management's Discussion & Analysis (MD&A)
- Removed:
- Business Update section removed from the newer filing, dated 2026-05-05, which described the Avadel Acquisition completed on February 12, 2026, adding LUMRYZ, consideration of $21.00 per Avadel Share plus a contingent $1.50 CVR, and costs of approximately $34.8 million for the three months ended March 31, 2026.
- Notes:
- The newer MD&A excerpt is truncated and appears to consist only of a heading and first sentence, so no other comparative content was available beyond the Business Update removal.
Risk Factors
- Added:
- Newer filing (2026-07-28) added "REVITALYZ SM" to the list of Alkermes-owned trademarks and service marks.
- Newer filing (2026-07-28) added "and service marks" to the sentence describing owned U.S. federal trademark registrations and other trademarks.
- Newer filing (2026-07-28) removed the reference to "LLC;" that appeared in the older filing's list of trademark attributions.
- Removed:
- Older filing (2026-05-05) contained "and other trademarks (\u201c TM \u201d)" without mention of service marks in that phrase.
- Older filing (2026-05-05) listed "REVITALYZ SM" was not present among Alkermes-owned trademarks.
- Older filing (2026-05-05) included "LLC;" after the Johnson & Johnson trademark list, which was removed in the newer filing.
- Reworded:
- Newer filing (2026-07-28) changed the trademark ownership sentence from "various U.S. federal trademark registrations (\u201c ® \u201d) and other trademarks (\u201c TM \u201d)" to "various U.S. federal trademark registrations (\u201c ® \u201d) and other trademarks (\u201c TM \u201d) and service marks".
- Newer filing (2026-07-28) changed the Alkermes-owned trademark list by inserting "REVITALYZ SM" after "NANOCRYSTAL ®" and before "VIVITROL ®".
- Newer filing (2026-07-28) changed the Johnson & Johnson trademark attribution by removing the stray "LLC;" element present in the older filing.
- Notes:
- The provided excerpts are labeled 'Risk Factors' but predominantly contain financial statements and general introductory notes; no substantive risk factor text changes were identifiable in the supplied material.
- The newer excerpt is truncated at the statement of cash flows and may not include the complete section; comparison is limited to the text actually provided.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 8 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-040 buys · 1 sell ($83455) — 1 selling insider
- Last 90 days · read to 2026-10-040 buys · 8 sells ($4M) — 4 selling insiders
- Last 180 days · read to 2026-10-040 buys · 17 sells ($6M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-10-02. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ALKS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for ALKS from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Short interest (FINRA)
ALKS had 15,156,775 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ALKS had 9.03% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.7 days to cover at the same settlement.
- Reported short interest (shares) 15,156,775
- Short interest (% of shares outstanding) 9.03%
- Prior settlement (shares) 14,717,404
- Reported change 2.99%
- Days to cover (reported) 10.7
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Johnson & Johnson (JNJ)
- Biogen (BIIB)
- Otsuka Pharmaceutical
- Lundbeck
- Acadia Pharmaceuticals (ACAD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ALKS vs…
Frequently asked questions
What does ALKERMES (ALKS) do?
Alkermes is a global biopharmaceutical company focused on the development of medicines in the field of neuroscience. The company maintains a portfolio of proprietary products for the treatment of alcohol and opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. It also operates a pipeline of clinical and preclinical candidates targeting neurological disorders including idiopathic hypersomnia, ADHD, and fatigue associated with multiple sclerosis and Parkinson’s disease.
What sector is ALKERMES (ALKS) in?
ALKERMES (ALKS) is classified in the Health Care sector. Its industry is Neuroscience Pharmaceuticals. It trades on NASDAQ.
Who are ALKERMES's (ALKS) competitors?
Notable peers of ALKERMES (ALKS) include Johnson & Johnson, Biogen, Otsuka Pharmaceutical, Lundbeck and Acadia Pharmaceuticals. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in ALKS?
Yes — we hold 1 matched STOCK Act disclosure for ALKS from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is ALKERMES (ALKS) overbought or oversold right now?
ALKERMES (ALKS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 33, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ALKS come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.